日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Real-world treatment patterns and outcomes in HER2-low, HR+ metastatic breast cancer patients previously treated with endocrine therapy in the United States

美国既往接受过内分泌治疗的HER2低表达、HR+转移性乳腺癌患者的真实世界治疗模式和结果

Modi, Shanu; Byng, Danalyn; Zhang, Suyuan; Xiong, Yan; Hunter, Shannon; Dunton, Kyle; Harding, Tara; Jacot, William

Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial

曲妥珠单抗德鲁替康治疗HER2低表达转移性乳腺癌:随机3期DESTINY-Breast04试验的长期生存分析

Modi, Shanu; Jacot, William; Iwata, Hiroji; Park, Yeon Hee; Vidal Losada, Maria; Li, Wei; Tsurutani, Junji; Ueno, Naoto T; Zaman, Khalil; Prat, Aleix; Papazisis, Konstantinos; Rugo, Hope S; Yamashita, Toshinari; Harbeck, Nadia; Im, Seock-Ah; De Laurentiis, Michelino; Pierga, Jean-Yves; Wang, Xiaojia; Gombos, Andrea; Tokunaga, Eriko; Orbegoso Aguilar, Cecilia; Yung, Lotus; Xiao, Feng; Cheng, Yingkai; Cameron, David

Cardiac Safety of Reduced Cardiotoxicity Surveillance During HER2-Targeted Therapy

HER2靶向治疗期间减少心脏毒性监测的心脏安全性

Yu, Anthony F; Dang, Chau T; Moskowitz, Chaya S; Mishra Meza, Akriti; DeFusco, Patricia; Oligino, Eric; Chen, Carol L; Sanford, Rachel; Drullinsky, Pamela; Bromberg, Jacqueline; Wong, Serena; Modi, Shanu; Jorgensen, Justine; Oeffinger, Kevin C; Steingart, Richard M; Liu, Jennifer E

Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBC

DESTINY-Breast04 研究的患者报告结局:曲妥珠单抗德鲁替康与医生选择的化疗方案在 HER2 低表达转移性乳腺癌患者中的疗效比较

Ueno, Naoto T; Cottone, Francesco; Dunton, Kyle; Jacot, William; Yamashita, Toshinari; Sohn, Joohyuk; Tokunaga, Eriko; Prat, Aleix; Tsurutani, Junji; Park, Yeon Hee; Rugo, Hope S; Xu, Binghe; Cardoso, Fatima; Mitri, Zahi; Mahtani, Reshma; Aguilar, Cecilia Orbegoso; Xiao, Feng; Harbeck, Nadia; Cameron, David A; Modi, Shanu

Characterization of the safety profile of trastuzumab deruxtecan by dose: a pooled analysis across DESTINY studies

按剂量划分的曲妥珠单抗德鲁西替康安全性特征:DESTINY 研究的汇总分析

Park, Yeon Hee; Cortes, Javier; Modi, Shanu; Hurvitz, Sara A; Bianchini, Giampaolo; Iwata, Hiroji; Shitara, Kohei; Siena, Salvatore; Goto, Yasushi; Ku, Geoffrey Y; Powell, Charles A; Swain, Sandra M; Arunachalam, Meena; Janek, Martin; Cheng, Yingkai; Chu, Changan; Verma, Purnima; Kuptsova-Clarkson, Nataliya; Mathias, Elton; Goodman, Erin; Rugo, Hope S

Antibody drug conjugates in metastatic brain tumors: current landscape, therapeutic potential and challenges

抗体药物偶联物在转移性脑肿瘤中的应用:现状、治疗潜力和挑战

Robert, Stephanie M; Toth, Allison; Lev, Sapir; Bowden, Stephen G; Yu, Yao; Imber, Brandon S; Boire, Adrienne; Drago, Joshua Z; Modi, Shanu; Moss, Nelson S

Treatment patterns and outcomes in HER2-low metastatic breast cancer patients previously treated with chemotherapy: a US real-world cohort study

既往接受过化疗的HER2低表达转移性乳腺癌患者的治疗模式和预后:一项美国真实世界队列研究

Modi, Shanu; Zhang, Suyuan; Byng, Danalyn; Hunter, Shannon; Strübing, Alessandria; Xiong, Yan; Dunton, Kyle; Mbanya, Zacharie; Jacot, William

Evaluating post-T-DXd treatment strategies in HER2-positive metastatic breast cancer

评估 HER2 阳性转移性乳腺癌患者接受 T-DXd 治疗后的治疗策略

Zelizer, Sophia; Gallagher, Grace B; Gonen, Mithat; Dang, Chau; Modi, Shanu; Chandarlapaty, Sarat; Drago, Joshua Z

Local Therapy for Isolated Central Nervous System Progression Among Patients Receiving Antibody-Drug Conjugate Therapy

抗体药物偶联疗法治疗中孤立性中枢神经系统进展的局部治疗

Lebow, Emily S; Eichholz, Jordan; Zhang, Zhigang; Toumbacaris, Nicolas; Imber, Brandon; Chen, Linda; LaPlant, Quincey; Yamada, Josh; Pike, Luke R G; Modi, Shanu; Seidman, Andrew D; Beal, Kathryn; Moss, Nelson S; Yu, Yao

Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer: a plain language summary of the DESTINY-Breast04 study

曲妥珠单抗德鲁替康治疗既往接受过治疗的HER2低表达晚期乳腺癌:DESTINY-Breast04研究的简明摘要

Modi, Shanu